Efficacy News and Research

RSS
Javelin Pharmaceuticals submits an NDA for Dyloject Injection

Javelin Pharmaceuticals submits an NDA for Dyloject Injection

Ellipse Technologies presents clinical results of its MAGEC System study

Ellipse Technologies presents clinical results of its MAGEC System study

FDA approves revised clinical trial protocol for CytRx' arimoclomol

FDA approves revised clinical trial protocol for CytRx' arimoclomol

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

Sepracor to present clinical study data of STEDESA at the 2009 AES meeting

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

International AIDS Vaccine Initiative calls for redoubled efforts in vaccine development

International AIDS Vaccine Initiative calls for redoubled efforts in vaccine development

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

Development of novel virus can lead to new therapeutic strategy to combat cancer

Development of novel virus can lead to new therapeutic strategy to combat cancer

Bioactive sponge to eliminate normally fatal tumors

Bioactive sponge to eliminate normally fatal tumors

Boehringer Ingelheim to announce positive results from its RE-COVER study

Boehringer Ingelheim to announce positive results from its RE-COVER study

Results from second Phase III placebo controlled study of EXPAREL announced

Results from second Phase III placebo controlled study of EXPAREL announced

J&JPRD submits an NDA for tapentadol ER tablets

J&JPRD submits an NDA for tapentadol ER tablets

OptiNose announces study results of intranasal device for treating chronic rhinosinusitis with nasal polyps

OptiNose announces study results of intranasal device for treating chronic rhinosinusitis with nasal polyps

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A can use new treatment option, XYNTHA

New patented technology to combat healthcare-associated infections

New patented technology to combat healthcare-associated infections

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

MicroDose Therapeutx acquires a portfolio of compounds from Epix Pharmaceuticals

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.